Reason argues that letting licensed pharmacies make BPC-157, MOTS-c and four other peptides beats leaving buyers to research-only sellers.
Recap by typeshit. Full story at Reason Magazine.
Per @pamelajeannoble, the letter flags contamination risks, manufacturing conditions and compounded copies resembling approved drugs.
Gounder notes the policy requires no testing of finished vials or deadline for side effect reports, and public comments on the draft run through November 13.
Healio
Durrani tells Healio the move bypassed rulemaking and FDA scientists, and warns patients may wrongly read it as FDA approval while long-term data is missing.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
The cash flow estimate points to the retatrutide phase 3 win and a deeper pipeline as reasons Lilly's value could sit above today's share price.
The efpeglenatide shot costs about 129,800 won for the first four weeks, and Korean phase 3 data showed 9.75% average weight loss over 40 weeks.
Loading…